Pdc*Line Pharma
ID: 7173212Novel class of off-the-shelf cancer immunotherapies based on a proprietary Plasmacytoid Dendritic Cell line pre-loaded with peptides
2
Funding Rounds
$43.9m
Money raised
Recent Funding Rounds
Unlock Complete Company Intelligence
Access comprehensive data and insights available only to Seedtable members
Financial Details
- • Complete funding history and valuations
- • Revenue estimates and financial metrics
- • Investment round details and terms
People & Contacts
- • Complete leadership team profiles
- • Contact information and email addresses
- • Board members and advisors
Market Intelligence
- • Competitive landscape analysis
- • Market position and growth metrics
- • Industry benchmarking data
Premium Tools
- • Export data and generate reports
- • Save companies to custom watchlists
- • API access for data integration
Join 10,000+ Professionals
Trusted by investors, founders, and analysts worldwide
Access detailed insights on 71,000+ companies worldwide
Funding
Funding series
Funding Series Analysis
The company Pdc*Line Pharma has raised a total of $30.9m in funding over 2 rounds.
Key Insights:
- PDC*line pharma January 2024 Series B Funding Round: $8.7m
- Pdc*Line Pharma Series B round, January 2020: $22.2m
Industries
Pdc*Line Pharma is active in the following industries: